Menu
FDA DECISION ·
Pluvicto + ARPI
lutetium Lu 177 vipivotide tetraxetan with an androgen receptor pathway inhibitor · Novartis
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with PSMA-positive metastatic prostate cancer that is androgen pathway modulation-naïve or -sensitive, in combination with an androgen receptor pathway inhibitor.
LAMPGEN ANALYSIS
Why it matters
Radioligand therapy moves into an earlier metastatic treatment setting. PSMAddition compared adding Pluvicto with an androgen pathway inhibitor alone.
What research teams should watch
PSMA imaging, isotope supply, nuclear medicine staffing and radiation-safety workflows affect when patients can start. Coverage should separate an approved option from local delivery capacity.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
PSMA-selected radioligand studiesPRIMARY RECORDS